Moors & Cabot Inc. Sells 192 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Moors & Cabot Inc. trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 23,153 shares of the biopharmaceutical company’s stock after selling 192 shares during the period. Moors & Cabot Inc.’s holdings in Gilead Sciences were worth $1,941,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Swedbank AB bought a new position in shares of Gilead Sciences in the first quarter worth $134,489,000. International Assets Investment Management LLC raised its position in shares of Gilead Sciences by 8,238.4% in the third quarter. International Assets Investment Management LLC now owns 1,642,504 shares of the biopharmaceutical company’s stock worth $137,708,000 after buying an additional 1,622,806 shares in the last quarter. Pacer Advisors Inc. raised its position in shares of Gilead Sciences by 24.7% in the second quarter. Pacer Advisors Inc. now owns 7,889,663 shares of the biopharmaceutical company’s stock worth $541,310,000 after buying an additional 1,564,792 shares in the last quarter. Deerfield Management Company L.P. Series C purchased a new stake in shares of Gilead Sciences in the second quarter worth $102,298,000. Finally, Assenagon Asset Management S.A. raised its position in shares of Gilead Sciences by 159.8% in the third quarter. Assenagon Asset Management S.A. now owns 2,337,717 shares of the biopharmaceutical company’s stock worth $195,994,000 after buying an additional 1,437,842 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on GILD shares. Leerink Partners upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $74.00 to $96.00 in a research report on Monday, October 21st. Truist Financial increased their price objective on Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research report on Friday, November 8th. Cantor Fitzgerald increased their price objective on Gilead Sciences from $70.00 to $80.00 and gave the stock a “neutral” rating in a research report on Thursday, November 7th. Wells Fargo & Company raised their price target on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Finally, Wolfe Research started coverage on Gilead Sciences in a research report on Friday, November 15th. They set an “outperform” rating and a $110.00 price target on the stock. Eleven analysts have rated the stock with a hold rating, eleven have assigned a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $94.00.

Gilead Sciences Stock Up 1.0 %

NASDAQ GILD opened at $88.63 on Thursday. The business’s 50-day moving average is $87.15 and its 200 day moving average is $76.52. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The stock has a market capitalization of $110.46 billion, a PE ratio of 984.78, a PEG ratio of 2.74 and a beta of 0.17. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $98.90.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. The business had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business’s revenue was up 7.0% on a year-over-year basis. During the same period in the previous year, the firm posted $2.29 EPS. Sell-side analysts forecast that Gilead Sciences, Inc. will post 4.38 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be issued a dividend of $0.77 per share. The ex-dividend date is Friday, December 13th. This represents a $3.08 annualized dividend and a dividend yield of 3.48%. Gilead Sciences’s payout ratio is 3,422.22%.

Insider Activity

In related news, insider Merdad Parsey sold 25,590 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the transaction, the insider now directly owns 99,599 shares in the company, valued at $9,113,308.50. The trade was a 20.44 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the transaction, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. The trade was a 27.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 56,947 shares of company stock worth $4,968,674. Insiders own 0.29% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.